Overall, these studies demonstrate that specific PCa models are highly dependent on MCL1 for survival and interrogation of the underlying mechanisms that drive sensitivity will support the clinical development of MCL1 inhibition, biomarker stratified, treatment approaches for lethal PCa. The gene discussed is MCL1; the disease is posterior cortical atrophy.